Form 4: Royalty Pharma CFO Acquires Shares via Equity Award

Royalty Pharma EVP and CFO Terrance P. Coyne acquired 24,263 Class A Ordinary Shares through the settlement of Equity Performance Awards.

Summary

• Terrance P. Coyne, EVP and CFO of Royalty Pharma, acquired 24,263 Class A Ordinary Shares on May 6, 2026.
• The acquisition was made via the settlement of Equity Performance Awards and was exempt under Rule 16b-3.
• Following the transaction, the reporting person holds 64,399 shares indirectly through TPC RP EPA1 LLC.
• The reporting person maintains additional indirect holdings, including interests exchangeable into over 8 million Class A Ordinary Shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding executive compensation and ownership changes.

Positives

• The CFO increased his beneficial ownership stake in the company, signaling alignment with shareholder interests.
• The acquisition was part of a standard equity performance award settlement, indicating the achievement of pre-defined performance metrics.

Negatives

• None identified.

Risks

• The value of the underlying Class A Ordinary Shares is subject to market volatility.
• Vesting conditions apply to the Class E Ordinary Shares of Royalty Pharma Holdings Ltd held by the reporting person.

Future Outlook

No specific forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider equity award settlements are standard corporate governance practices in the pharmaceutical royalty sector, reflecting the conversion of long-term incentive plans into equity ownership.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices observed in large-cap pharmaceutical and biotech firms.
• The use of Rule 16b-3 for exempt acquisitions is consistent with SEC compliance standards for public company officers.

Stakeholder Impact

• Increased alignment between the CFO and shareholders due to higher equity ownership.

Next Steps

• None mentioned.

Key Dates

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, CFO, Equity Compensation